Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$16.75

-0.15 (-0.89%)

, NTLA

Intellia Therapeutics

$15.23

-0.88 (-5.46%)

09:51
08/03/17
08/03
09:51
08/03/17
09:51

Crispr stocks rise after scientists successfully fix disease mutation in embryo

Shares of Crispr Therapeutics are rising in early trading after a team of scientists reported that they were successful in editing the DNA in human embryos to correct a pathogenic gene mutation. The study, published online Wednesday in the journal Nature, described the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with "precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response." Crispr Therapeutics (CRSP), which is a publicly traded company pursuing CRISPR treatments, is up 2.6% in early trading. Intellia Therapeutics (NTLA) and Editas Medicine (EDIT), which are also pursuing CRISPR treatments, are up 1.5% and 7.5%, respectively. Reference Link

CRSP

Crispr Therapeutics

$16.75

-0.15 (-0.89%)

NTLA

Intellia Therapeutics

$15.23

-0.88 (-5.46%)

EDIT

Editas Medicine

$15.81

-0.58 (-3.54%)

  • 15

    Aug

CRSP Crispr Therapeutics
$16.75

-0.15 (-0.89%)

07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
07/13/17
RHCO
07/13/17
INITIATION
Target $16
RHCO
Hold
CRISPR Therapeutics initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.
03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.
NTLA Intellia Therapeutics
$15.23

-0.88 (-5.46%)

07/20/17
JEFF
07/20/17
NO CHANGE
Target $36
JEFF
Buy
Intellia should be bought for long-term opportunity, says Jefferies
After touring the company's labs, Jefferies analyst Maury Raycroft recommends buying shares of Intellia Therapeutics for the company's long-term opportunity. The analyst keeps a Buy rating on the shares with a $36 price target.
05/03/17
FBCO
05/03/17
NO CHANGE
Target $24
FBCO
Outperform
Intellia Therapeutics price target lowered to $24 from $39 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Intellia Therapeutics to $24 from $39 saying that while she still likes it, big upside is likely capped until the company moves forward toward proof of concept. Young reiterates an Outperform rating on the shares.
05/31/17
JEFF
05/31/17
NO CHANGE
Target $33
JEFF
Buy
Intellia Therapeutics weakness a buying opportunity, says Jefferies
Jefferies analyst Maury Raycroft said weakness in Intellia Therapeutics shares in reaction to an article published in Nature Methods is a buying opportunity. The analyst said the story is "flawed overall" as it draws conclusions based on assessment of two experiments in mice that have different genetic makeup compared to a single control mouse, combined with other genetic variables, that may explain the article's conclusions. Raycroft said the story should not impact shares and reiterates his Buy rating and $33 price target on Intellia Therapeutics.
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Intellia Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann stated Intellia Therapeutics (NTLA) with a Perform rating saying the company is currently in a weaker patent position than competitor Editas Medicine (EDIT). The analyst, however, believes Intellia has the strongest partners among the CRISPR-based companies.
EDIT Editas Medicine
$15.81

-0.58 (-3.54%)

07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Editas Medicine initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Editas Medicine (EDIT) with a Perform rating saying that while the company currently has the strongest patent position among its CRISPR-based peers, the shares are fairly valued.
07/13/17
RHCO
07/13/17
INITIATION
Target $17
RHCO
Hold
Editas Medicine initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated Editas Medicine with a Hold and a $17 price target.

TODAY'S FREE FLY STORIES

ONDK

On Deck Capital

$8.09

0.6 (8.01%)

07:32
07/19/18
07/19
07:32
07/19/18
07:32
Downgrade
On Deck Capital rating change  »

Morgan Stanley sees On…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 15

    Aug

  • 16

    Aug

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:32
07/19/18
07/19
07:32
07/19/18
07:32
Earnings
Breaking Earnings news story on Alliance Data »

Alliance Data backs FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:31
07/19/18
07/19
07:31
07/19/18
07:31
Earnings
Alliance Data backs FY18 core EPS view $22.50 to $23.00, consensus $22.57 »

CEO Heffernan continued:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

DPZ

Domino's Pizza

$283.74

1.74 (0.62%)

07:31
07/19/18
07/19
07:31
07/19/18
07:31
Earnings
Domino's Pizza reports Q2 adjusted EPS $1.84, consensus $1.75 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 21

    Sep

  • 05

    Oct

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Earnings
Alliance Data reports Q2 core EPS $5.01, consensus $4.66 »

Reports Q2 revenue $1.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

LONE

Lonestar Resources

$10.37

0.42 (4.22%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Initiation
Lonestar Resources initiated  »

Lonestar Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

CMCSA

Comcast

$34.03

-0.23 (-0.67%)

, FOXA

21st Century Fox

$46.69

0.22 (0.47%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

CMCSA

Comcast

$34.03

-0.23 (-0.67%)

FOXA

21st Century Fox

$46.69

0.22 (0.47%)

GM

General Motors

$39.87

-0.185 (-0.46%)

PZZA

Papa John's

$53.60

2.06 (4.00%)

HPQ

HP Inc.

$23.54

-0.06 (-0.25%)

GOGO

Gogo

$3.91

0.15 (3.99%)

MDR

McDermott

$17.97

-0.075 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 31

    Jul

SQ

Square

$68.30

-0.02 (-0.03%)

07:28
07/19/18
07/19
07:28
07/19/18
07:28
Upgrade
Square rating change  »

Square upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 15

    Aug

  • 16

    Aug

MEET

Meet Group

$4.14

0.08 (1.97%)

07:26
07/19/18
07/19
07:26
07/19/18
07:26
Upgrade
Meet Group rating change  »

Meet Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$2.86

-0.1 (-3.38%)

07:26
07/19/18
07/19
07:26
07/19/18
07:26
Recommendations
Amarin analyst commentary  »

Amarin's Vascepa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$111.52

1.01 (0.91%)

07:25
07/19/18
07/19
07:25
07/19/18
07:25
Upgrade
JPMorgan rating change  »

JPMorgan upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

EBAY

eBay

$37.95

0.13 (0.34%)

07:25
07/19/18
07/19
07:25
07/19/18
07:25
Recommendations
eBay analyst commentary  »

eBay price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIV

F5 Networks

$179.52

2.86 (1.62%)

07:24
07/19/18
07/19
07:24
07/19/18
07:24
Downgrade
F5 Networks rating change  »

Morgan Stanley sees risk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 08

    Aug

CMG

Chipotle

$453.56

0.77 (0.17%)

, SBUX

Starbucks

$51.15

-0.12 (-0.23%)

07:24
07/19/18
07/19
07:24
07/19/18
07:24
Recommendations
Chipotle, Starbucks analyst commentary  »

Wedbush cautious on…

CMG

Chipotle

$453.56

0.77 (0.17%)

SBUX

Starbucks

$51.15

-0.12 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

PTCT

PTC Therapeutics

$35.02

-0.19 (-0.54%)

07:23
07/19/18
07/19
07:23
07/19/18
07:23
Initiation
PTC Therapeutics initiated  »

PTC Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$37.75

-0.35 (-0.92%)

07:22
07/19/18
07/19
07:22
07/19/18
07:22
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$174.38

5.77 (3.42%)

07:20
07/19/18
07/19
07:20
07/19/18
07:20
Recommendations
M&T Bank analyst commentary  »

M&T Bank price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
07/19/18
07/19
07:20
07/19/18
07:20
General news
Treasury Market Outlook: Treasury yields have extended slightly higher »

Treasury Market Outlook:…

WRD

WildHorse Resource

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
WildHorse Resource initiated  »

WildHorse Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 19

    Aug

ARA

American Renal Associates

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
American Renal Associates initiated  »

American Renal Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIG

Big Lots

$42.76

0.39 (0.92%)

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
Big Lots initiated  »

Big Lots initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:18
07/19/18
07/19
07:18
07/19/18
07:18
General news
Futures lower as trade war rhetoric, earnings reporting continues »

Stock futures are…

LITE

Lumentum

$59.30

-0.05 (-0.08%)

, VIAV

Viavi

$10.39

-0.09 (-0.86%)

07:17
07/19/18
07/19
07:17
07/19/18
07:17
Recommendations
Lumentum, Viavi, Apple analyst commentary  »

JPMorgan raises 3D…

LITE

Lumentum

$59.30

-0.05 (-0.08%)

VIAV

Viavi

$10.39

-0.09 (-0.86%)

AAPL

Apple

$190.43

-1.12 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 14

    Aug

HNHPF

Hon Hai Precision

$0.00

(0.00%)

07:17
07/19/18
07/19
07:17
07/19/18
07:17
Periodicals
Foxconn interested in webcast business opportunities, DigiTimes reports »

Foxconn has been building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$102.98

1.84 (1.82%)

07:15
07/19/18
07/19
07:15
07/19/18
07:15
Recommendations
American Express analyst commentary  »

American Express Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.